ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026
Laboratory Challenges in the Era of Novel Haemophilia Therapies.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Haemophilia: Novel Therapies and Diagnostic Challenges.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent advances in haemophilia A and B treatment, including extended half-life (EHL) factor concentrates, factor VIII (FVIII)-mimetic antibodies, gene therapies, and rebalancing agents, have substantially improved prophylaxis and bleed prevention. However, these therapeutic innovations have also introduced significant analytical challenges for laboratory monitoring. Conventional coagulation assays, particularly one-stage clotting assays and chromogenic substrate assays, frequently show assay-dependent discrepancies when applied to modified factor molecules, transgene-derived coagulation factors, or nonfactor therapies. In addition, antidrug antibodies (ADAs) against replacement products and novel biologics require adapted diagnostic strategies. Summary: This review discusses current laboratory challenges associated with modern haemophilia therapies. The effects of EHL factor concentrates on FVIII/FIX activity measurements, assay discrepancies in gene therapy, and assay interferences caused by FVIII-mimetic antibodies are summarized. Furthermore, analytical considerations for rebalancing therapies targeting antithrombin or tissue factor pathway inhibitor are addressed. The review also outlines current approaches for inhibitor and ADA testing in the setting of modified factor products and nonfactor therapies. In addition, the role of global haemostatic assays, particularly thrombin generation assays (TGAs), as emerging tools for integrative assessment of coagulation potential is discussed. Key Messages: Modern haemophilia therapies substantially affect the performance and interpretation of conventional coagulation assays and require therapy-specific analytical strategies. Reliable laboratory monitoring depends on detailed knowledge of assay characteristics, therapy-associated interferences, and appropriate methodological adaptations. Although global assays such as TGAs are increasingly investigated as integrative monitoring tools, further harmonization and clinical validation are required before widespread routine implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.